Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Panel Calls for Fact-Finding Study for Annual NHI Price Revision
October 3, 2014
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
- PMDA Evaluating Xtandi for Risk of Thrombocytopenia
September 30, 2014
- MHLW OKs 19 Products Including MSD’s Insomnia Drug Suvorexant
September 29, 2014
- Daclatasvir/Asunaprevir Combination Therapy for Hepatitis C Now Eligible for Medical Subsidy: MHLW
September 26, 2014
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
- MHLW Guidelines to Call for Thorough Internal Communications at Pharmas after Novartis’ Delayed ADR Reporting
September 19, 2014
- MHLW Official Concerned about Generic Codevelopment, but Denies Plans to Press for Industry Consolidation
September 19, 2014
- Selexipag, 4 Other APIs Designated as Orphan Drugs
September 19, 2014
- MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals
September 17, 2014
- Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs
September 17, 2014
- MHLW Orders Revision of Package Insert for Lyrica
September 17, 2014
- PMDA Issues Alert on Administration of ARBs and ACE Inhibitors in Pregnant Women
September 12, 2014
- US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights
September 12, 2014
- EAD Director to Visit 5 Public Hospital Groups to Encourage Quick Settlement of Price Negotiations
September 12, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…